undamentalytics Newsletter
Sign in

Onconetix, Inc. balance sheet

At the end of fiscal 2025, Onconetix, Inc. had total assets of $24.9m, total liabilities of $9.2m and shareholders' equity of $15.8m. It held $5.2m in cash against $0 of debt: net cash of $5.2m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents5156
Receivables0000
Inventory0000
Total current assets6167
Goodwill56271910
Total assets88282516
Accounts payable5422
Total current liabilities171893
Long-term debt0———
Total debt10900
Total liabilities221993
Shareholders' equity−691613
Non-controlling interests and other (assets − liabilities − equity)711——
Net debt (negative = net cash)59−5−6
Shares outstanding———4m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CRDF vs ONCOMNOV vs ONCOONCO vs STTK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Onconetix, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Onconetix, Inc.